NF2-related schwannomatosis: A view from within the inner ear

被引:0
|
作者
Brown, Eleanor D. [1 ]
Nassar, Shada [1 ]
Jagger, Daniel J. [1 ]
机构
[1] UCL, UCL Ear Inst, 332 Grays Inn Rd, London WC1X 8EE, England
关键词
Cochlea; Hearing loss; Meningioma; Neurofibromatosis; Schwannoma; BILATERAL ACOUSTIC NEUROFIBROMATOSIS; VESTIBULAR SCHWANNOMAS; EARLY HISTORY; TYPE-2; DEAFNESS; NEUROMA; FAMILY; NF2;
D O I
10.1016/j.heares.2025.109226
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) is an autosomal dominant disorder associated with the growth of bilateral schwannomas on the cochleo-vestibular nerves and meningiomas. NF2-SWN is caused by pathogenic variations in the NF2, moesin-ezrin-radixin-like (MERLIN) tumour suppressor gene. The mostly benign tumours can cause progressive sensorineural hearing loss, tinnitus and balance dysfunction. Outside the inner ear, tumours grow on other intra-cranial nerves, leading to further neurological issues and shortened life-expectancy. Here we re-evaluate some historic cases from our human temporal bone collection, and we review similar instances from the literature to highlight the structural and functional effects of such tumours on the cochlea and vestibular organs. Tumour growth is associated with the remodelling of sensory and ion-transporting epithelia, the loss of afferent neurons and hair cells, and signs of fluid dysregulation. These cases demonstrate the aggressive nature of this disease and the difficulties of surgically excising the bilateral tumours. They also emphasise the need for novel therapies that can slow or prevent tumour growth to preserve sensory function in people living with NF2-SWN.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Gene therapy and genome-editing for schwannoma in NF2-related schwannomatosis: current understanding and future directions
    Tamura, Ryota
    Yo, Masahiro
    Toda, Masahiro
    JOURNAL OF NEURO-ONCOLOGY, 2025,
  • [32] Correlation between genotype and phenotype with special attention to hearing in 14 Japanese cases of NF2-related schwannomatosis
    Oishi, Naoki
    Noguchi, Masaru
    Fujioka, Masato
    Nara, Kiyomitsu
    Wasano, Koichiro
    Mutai, Hideki
    Kawakita, Rie
    Tamura, Ryota
    Karatsu, Kosuke
    Morimoto, Yukina
    Toda, Masahiro
    Ozawa, Hiroyuki
    Matsunaga, Tatsuo
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis
    Smith, Miriam J.
    Perez-Becerril, Cristina
    van der Meer, Mwee
    Burghel, George J.
    Waller, Sarah J.
    Carney, Megan
    Bunstone, Sancha
    Fryer, Katherine
    Bowers, Naomi L.
    Hartley, Claire L.
    Smith, Philip T.
    Rutherford, Scott A.
    Freeman, Simon R.
    Lloyd, Simon K. W.
    Pathmanaban, Omar N.
    King, Andrew Thomas
    Halliday, Dorothy
    Duff, Chris
    Evans, D. Gareth
    JOURNAL OF MEDICAL GENETICS, 2024,
  • [34] Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro
    Catasus, Nuria
    Rosas, Inma
    Bonache, Sandra
    Negro, Alex
    Torres-Martin, Miguel
    Plana-Pla, Adria
    Salvador, Hector
    Serra, Eduard
    Blanco, Ignacio
    Castellanos, Elisabeth
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 30 : 493 - 505
  • [35] Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosis
    Smith, Miriam J.
    Perez-Becerril, Cristina
    van der Meer, Mwee
    Burghel, George J.
    Waller, Sarah J.
    Carney, Megan
    Bunstone, Sancha
    Fryer, Katherine
    Bowers, Naomi L.
    Hartley, Claire L.
    Smith, Philip T.
    Rutherford, Scott A.
    Freeman, Simon R.
    Lloyd, Simon K. W.
    Pathmanaban, Omar N.
    King, Andrew Thomas
    Halliday, Dorothy
    Duff, Chris
    Evans, D. Gareth
    JOURNAL OF MEDICAL GENETICS, 2024, 61 (11) : 1011 - 1015
  • [36] Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis
    Tamura, Ryota
    Yamanobe, Yoshiharu
    Fujioka, Masato
    Morimoto, Yukina
    Fukumura, Mariko
    Nakaya, Masato
    Oishi, Yumiko
    Sato, Mizuto
    Ueda, Ryo
    Fujiwara, Hirokazu
    Hikichi, Tetsuro
    Noji, Shinobu
    Oishi, Naoki
    Ozawa, Hiroyuki
    Ogawa, Kaoru
    Kawakami, Yutaka
    Ohira, Takayuki
    Yoshida, Kazunari
    Toda, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (21) : 2578 - 2587
  • [37] Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis
    Lu, Simeng
    Yin, Zhenzhen
    Chen, Jie
    Wu, Limeng
    Sun, Yao
    Gao, Xing
    Huang, Peigen
    Jordan, Justin T.
    Plotkin, Scott R.
    Xu, Lei
    CANCERS, 2024, 16 (11)
  • [38] Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis
    Dornhoffer, James R.
    Plitt, Aaron R.
    Lohse, Christine M.
    Driscoll, Colin L. W.
    Neff, Brian A.
    Saoji, Aniket A.
    Van Gompel, Jamie J.
    Link, Michael J.
    Carlson, Matthew L.
    OTOLOGY & NEUROTOLOGY, 2024, 45 (01) : 29 - 35
  • [39] Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma
    Plotkin, Scott R.
    Allen, Jeffrey
    Dhall, Girish
    Campian, Jian L.
    Clapp, D. Wade
    Fisher, Michael J.
    Jain, Rakesh K.
    Tonsgard, James
    Ullrich, Nicole J.
    Thomas, Coretta
    Edwards, Lloyd J.
    Korf, Bruce
    Packer, Roger
    Karajannis, Matthias A.
    Blakeley, Jaishri O.
    NEURO-ONCOLOGY, 2023, 25 (08) : 1498 - 1506
  • [40] Therapy of Sporadic and NF2-Related Vestibular Schwannoma
    Yao, Longping
    Alahmari, Mohammed
    Temel, Yasin
    Hovinga, Koos
    CANCERS, 2020, 12 (04)